Skip to main content
. 2020 Apr 22;15(2):284–294. doi: 10.5009/gnl19367

Fig. 3.

Fig. 3

Overall survival time and time-to-progression in the subgroup analysis. Comparison of survival (A) and time-to-progression (B) between the sorafenib monotherapy group, sorafenib with combination therapy group, hepatic arterial infusion chemotherapy (HAIC) monotherapy group and HAIC with combination therapy group.